Anti-Apolipoprotein A I antibody [G2] (ab58924)
Key features and details
- Mouse monoclonal [G2] to Apolipoprotein A I
- Suitable for: ELISA, IHC-Fr, WB
- Reacts with: Human
- Isotype: IgG1
Overview
-
Product name
Anti-Apolipoprotein A I antibody [G2]
See all Apolipoprotein A I primary antibodies -
Description
Mouse monoclonal [G2] to Apolipoprotein A I -
Host species
Mouse -
Specificity
This antibody reacts with both free human Apolipoprotein AI and High Density Lipoprotein (HDL) bearing Apolipoprotein AI, but does not cross react with Apolipoprotein E, B or Albumin. -
Tested applications
Suitable for: ELISA, IHC-Fr, WBmore details -
Species reactivity
Reacts with: Human -
Immunogen
Apolipoprotein AI from human plasma.
-
General notes
Affinity: Kd = 3nM (for human apolipoprotein A1).The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.
If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As
Properties
-
Form
Liquid -
Storage instructions
Shipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles. -
Storage buffer
Constituents: 1% Dextran, 1% Mannitol, 0.381% Sodium borate, 0.164% Sodium phosphate, 0.87% Sodium chloride
And salts -
Concentration information loading...
-
Purity
Protein A purified -
Clonality
Monoclonal -
Clone number
G2 -
Isotype
IgG1 -
Research areas
Associated products
-
Compatible Secondaries
-
Isotype control
-
Recombinant Protein
Applications
The Abpromise guarantee
Our Abpromise guarantee covers the use of ab58924 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
Application | Abreviews | Notes |
---|---|---|
ELISA |
Use at an assay dependent concentration.
|
|
IHC-Fr |
Use at an assay dependent concentration.
|
|
WB |
Use at an assay dependent concentration.
|
Notes |
---|
ELISA
Use at an assay dependent concentration. |
IHC-Fr
Use at an assay dependent concentration. |
WB
Use at an assay dependent concentration. |
Target
-
Function
Participates in the reverse transport of cholesterol from tissues to the liver for excretion by promoting cholesterol efflux from tissues and by acting as a cofactor for the lecithin cholesterol acyltransferase (LCAT). As part of the SPAP complex, activates spermatozoa motility. -
Tissue specificity
Major protein of plasma HDL, also found in chylomicrons. Synthesized in the liver and small intestine. -
Involvement in disease
Defects in APOA1 are a cause of high density lipoprotein deficiency type 2 (HDLD2) [MIM:604091]; also known as familial hypoalphalipoproteinemia (FHA). Inheritance is autosomal dominant.
Defects in APOA1 are a cause of the low HDL levels observed in high density lipoprotein deficiency type 1 (HDLD1) [MIM:205400]; also known as analphalipoproteinemia or Tangier disease (TGD). HDLD1 is a recessive disorder characterized by the absence of plasma HDL, accumulation of cholesteryl esters, premature coronary artery disease, hepatosplenomegaly, recurrent peripheral neuropathy and progressive muscle wasting and weakness. In HDLD1 patients, ApoA-I fails to associate with HDL probably because of the faulty conversion of pro-ApoA-I molecules into mature chains, either due to a defect in the converting enzyme activity or a specific structural defect in Tangier ApoA-I.
Defects in APOA1 are the cause of amyloid polyneuropathy-nephropathy Iowa type (AMYLIOWA) [MIM:107680]; also known as amyloidosis van Allen type or familial amyloid polyneuropathy type III. AMYLIOWA is a hereditary generalized amyloidosis due to deposition of amyloid mainly constituted by apolipoprotein A1. The clinical picture is dominated by neuropathy in the early stages of the disease and nephropathy late in the course. Death is due in most cases to renal amyloidosis. Severe peptic ulcer disease can occurr in some and hearing loss is frequent. Cataracts is present in several, but vitreous opacities are not observed.
Defects in APOA1 are a cause of amyloidosis type 8 (AMYL8) [MIM:105200]; also known as systemic non-neuropathic amyloidosis or Ostertag-type amyloidosis. AMYL8 is a hereditary generalized amyloidosis due to deposition of apolipoprotein A1, fibrinogen and lysozyme amyloids. Viscera are particularly affected. There is no involvement of the nervous system. Clinical features include renal amyloidosis resulting in nephrotic syndrome, arterial hypertension, hepatosplenomegaly, cholestasis, petechial skin rash. -
Sequence similarities
Belongs to the apolipoprotein A1/A4/E family. -
Post-translational
modificationsPalmitoylated.
Phosphorylation sites are present in the extracelllular medium. -
Cellular localization
Secreted. - Information by UniProt
-
Database links
- Entrez Gene: 335 Human
- Omim: 107680 Human
- SwissProt: P02647 Human
- Unigene: 93194 Human
-
Alternative names
- Apo-AI antibody
- ApoA I antibody
- ApoA-I antibody
see all
Protocols
Datasheets and documents
-
SDS download
-
Datasheet download
References (1)
ab58924 has been referenced in 1 publication.
- Chiang SY et al. Proteomic analysis and identification of aqueous humor proteins with a pathophysiological role in diabetic retinopathy. J Proteomics : (2011). WB ; Human . PubMed: 22200677